Quarterly report pursuant to Section 13 or 15(d)

Commitment and Contingencies - Additional Information (Details)

v3.20.2
Commitment and Contingencies - Additional Information (Details)
Jan. 21, 2020
USD ($)
RNL
$ / RNL
Nov. 18, 2015
USD ($)
Royalty-Linked Notes | Private Placement    
Other Commitments [Line Items]    
Aggregate principal amount $ 2,579,400  
Debt instrument outstanding portion | $ / RNL 0.04  
Debt instrument note price per unit | $ / RNL 2.00  
Debt instrument maturity date Dec. 31, 2045  
Debt instrument, aggregate potential payment capped value $ 160,000  
Debt instrument, aggregate potential payment capped rate 4,000  
Number of debt instruments within each notes | RNL 50  
Maximum return amount for each unit $ 8,000,000  
Pfizer License Agreement | Royalty-Linked Notes | Private Placement    
Other Commitments [Line Items]    
Aggregate principal amount $ 2,579,400  
Debt instrument outstanding portion | $ / RNL 0.04  
Debt instrument note price per unit | $ / RNL 2.00  
Debt instrument maturity date Dec. 31, 2045  
Debt instrument, aggregate potential payment capped value $ 160,000  
Debt instrument, aggregate potential payment capped rate 4,000  
Number of debt instruments within each notes | RNL 50  
Maximum return amount for each unit $ 8,000,000  
Pfizer License Agreement | Minimum    
Other Commitments [Line Items]    
Potential future regulatory milestone and sales milestone payments upon achievement of net sales   $ 250,000,000
Pfizer License Agreement | Maximum    
Other Commitments [Line Items]    
Potential future regulatory milestone and sales milestone payments upon achievement of net sales   $ 1,000,000,000